Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2483人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866627, encodeId=0220186662e68, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：鲁卡帕利单药维持治疗新发卵巢癌的3期临床试验结果, objectType=article, longId=728879, objectId=1cfae28879bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cfae28879bb, replyNumber=0, likeNumber=75, createdTime=2022-12-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cfae28879bb, moduleTitle=J Clin Oncol：鲁卡帕利单药维持治疗新发卵巢癌的3期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cfae28879bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866559, encodeId=80fe186655926, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Clin Oncol：晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效, objectType=article, longId=301250, objectId=210e30125037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210e30125037, replyNumber=0, likeNumber=62, createdTime=2022-10-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210e30125037, moduleTitle=Clin Oncol：晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=210e30125037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866404, encodeId=f6301866404b9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效, objectType=article, longId=264985, objectId=1e88264985e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e88264985e4, replyNumber=0, likeNumber=81, createdTime=2022-09-23, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e88264985e4, moduleTitle=Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e88264985e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866420, encodeId=37cd18664202b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：采用CAR T 细胞Axicabtagene ciloleucel治疗复发/难治性惰性非霍奇金淋巴瘤, objectType=article, longId=292051, objectId=1254292051ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1254292051ee, replyNumber=0, likeNumber=63, createdTime=2022-11-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1254292051ee, moduleTitle=Lancet Oncol：采用CAR T 细胞Axicabtagene ciloleucel治疗复发/难治性惰性非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1254292051ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866179, encodeId=2d5318661e94e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Avapritinib对比瑞戈非尼（Regorafenib）治疗局部进展不可切除或转移性胃肠道间质瘤的疗效：随机III期研究, objectType=article, longId=215316, objectId=4736215316ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4736215316ea, replyNumber=0, likeNumber=64, createdTime=2021-09-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4736215316ea, moduleTitle=J Clin Oncol：Avapritinib对比瑞戈非尼（Regorafenib）治疗局部进展不可切除或转移性胃肠道间质瘤的疗效：随机III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4736215316ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866533, encodeId=e4ab1866533bb, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后, objectType=article, longId=300086, objectId=ce6c30008640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce6c30008640, replyNumber=0, likeNumber=65, createdTime=2022-08-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce6c30008640, moduleTitle=Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce6c30008640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866514, encodeId=694a1866514ab, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Target Oncol:评估真实世界中符合和不符合AURA3研究标准患者二线使用奥希替尼治疗的疗效, objectType=article, longId=295710, objectId=a635295e103b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a635295e103b, replyNumber=0, likeNumber=71, createdTime=2022-04-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a635295e103b, moduleTitle=Target Oncol:评估真实世界中符合和不符合AURA3研究标准患者二线使用奥希替尼治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a635295e103b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866453, encodeId=93ac18664535c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异, objectType=article, longId=293862, objectId=e5bc2938625c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5bc2938625c, replyNumber=0, likeNumber=63, createdTime=2022-01-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5bc2938625c, moduleTitle=Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5bc2938625c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866141, encodeId=aa6c186614178, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, objectType=article, longId=213736, objectId=41a6213e36ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41a6213e36ec, replyNumber=0, likeNumber=87, createdTime=2022-02-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41a6213e36ec, moduleTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41a6213e36ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866385, encodeId=1dcc186638579, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, objectType=article, longId=221311, objectId=7491221311ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7491221311ab, replyNumber=0, likeNumber=80, createdTime=2022-08-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7491221311ab, moduleTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7491221311ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866482, encodeId=aedf1866482d9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, objectType=article, longId=295073, objectId=a9a02950e37b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a02950e37b, replyNumber=0, likeNumber=72, createdTime=2022-12-15, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a02950e37b, moduleTitle=Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a02950e37b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866454, encodeId=0664186645455, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：随机FinXX研究超10年OS结果表明加用卡培他滨至辅助化疗中可改善早期乳腺癌患者的预后, objectType=article, longId=293986, objectId=b19d2939860d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b19d2939860d, replyNumber=0, likeNumber=0, createdTime=2022-03-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b19d2939860d, moduleTitle=J Clin Oncol：随机FinXX研究超10年OS结果表明加用卡培他滨至辅助化疗中可改善早期乳腺癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b19d2939860d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866314, encodeId=1d9f18663149e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, objectType=article, longId=219184, objectId=9df12191846b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9df12191846b, replyNumber=0, likeNumber=69, createdTime=2021-11-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9df12191846b, moduleTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9df12191846b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866228, encodeId=5d0c1866228fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究, objectType=article, longId=217280, objectId=228d21e2804b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=228d21e2804b, replyNumber=0, likeNumber=83, createdTime=2022-05-18, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=228d21e2804b, moduleTitle=Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=228d21e2804b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866282, encodeId=45aa186628298, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：围手术期不同时间点CEA水平跟II期结直肠癌患者生存的关系, objectType=article, longId=218424, objectId=a09d218424bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a09d218424bf, replyNumber=0, likeNumber=144, createdTime=2021-12-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a09d218424bf, moduleTitle=Front Oncol：围手术期不同时间点CEA水平跟II期结直肠癌患者生存的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a09d218424bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866573, encodeId=e31018665e3e5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：基于大型人群队列探索胃腺癌骨转移的危险因素和预后, objectType=article, longId=301729, objectId=d731301e2947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d731301e2947, replyNumber=0, likeNumber=77, createdTime=2022-07-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d731301e2947, moduleTitle=Front Oncol：基于大型人群队列探索胃腺癌骨转移的危险因素和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d731301e2947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866574, encodeId=0f4f18665e4fc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：早期子宫内膜透明细胞癌患者行系统淋巴结切除术可改善患者预后, objectType=article, longId=301740, objectId=1ac9301e4007, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ac9301e4007, replyNumber=0, likeNumber=57, createdTime=2022-05-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ac9301e4007, moduleTitle=Front Oncol：早期子宫内膜透明细胞癌患者行系统淋巴结切除术可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ac9301e4007)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866601, encodeId=3cd218666019e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌, objectType=article, longId=727038, objectId=8cb4e270380d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cb4e270380d, replyNumber=0, likeNumber=72, createdTime=2022-09-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cb4e270380d, moduleTitle=JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cb4e270380d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866595, encodeId=0f8e1866595b2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：替雷利珠单抗二线治疗晚期/转移性食管鳞状细胞癌的效果, objectType=article, longId=724761, objectId=e0eae247611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0eae247611e, replyNumber=0, likeNumber=92, createdTime=2023-03-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0eae247611e, moduleTitle=J Clin Oncol：替雷利珠单抗二线治疗晚期/转移性食管鳞状细胞癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0eae247611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866490, encodeId=d4e3186649089, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效, objectType=article, longId=295135, objectId=2c9b295135ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c9b295135ea, replyNumber=0, likeNumber=77, createdTime=2022-09-10, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c9b295135ea, moduleTitle=Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c9b295135ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：鲁卡帕利单药维持治疗新发卵巢癌的3期临床试验结果

2022-12-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Clin Oncol：晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效

2022-10-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效

2022-09-23

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：采用CAR T 细胞Axicabtagene ciloleucel治疗复发/难治性惰性非霍奇金淋巴瘤

2022-11-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Avapritinib对比瑞戈非尼（Regorafenib）治疗局部进展不可切除或转移性胃肠道间质瘤的疗效：随机III期研究

2021-09-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后

2022-08-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Target Oncol:评估真实世界中符合和不符合AURA3研究标准患者二线使用奥希替尼治疗的疗效

2022-04-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异

2022-01-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析

2022-02-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究

2022-08-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：TNBC患者标准新辅助化疗中加入卡铂联合或不联合veliparib（维拉帕利）的疗效和安全性

2022-12-15

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：随机FinXX研究超10年OS结果表明加用卡培他滨至辅助化疗中可改善早期乳腺癌患者的预后

2022-03-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响

2021-11-08

爆笑小医 (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：吡咯替尼+长春瑞滨VS拉帕替尼+卡培他滨用于转移性HER-2阳性经治乳腺癌患者的疗效对比：多中心回顾性研究

2022-05-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：围手术期不同时间点CEA水平跟II期结直肠癌患者生存的关系

2021-12-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：基于大型人群队列探索胃腺癌骨转移的危险因素和预后

2022-07-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：早期子宫内膜透明细胞癌患者行系统淋巴结切除术可改善患者预后

2022-05-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：Vistusertib联合阿那曲唑治疗激素受体阳性子宫内膜癌

2022-09-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：替雷利珠单抗二线治疗晚期/转移性食管鳞状细胞癌的效果

2023-03-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效

2022-09-10

科室
- - 订阅+
  - 更多科室
工具
服务